Skip to main content

Table 2 Adverse Events

From: A randomized phase II trial evaluating the addition of low dose, short course sunitinib to docetaxel in advanced solid tumours

Toxicity

All grades

Grade 3 to 5

Docetaxel-sunitinib (N = 33)

Docetaxel alone (N = 35)

P value

Docetaxel-sunitinib (N = 33)

Docetaxel alone (N = 35)

P value

All toxicities

84.8%

91.4%

0.400

30.3%

42.9%

0.285

Fatigue

30.3%

45.7%

0.145

6.1%

0%

0.232

Peripheral neuropathy

27.3%

31.4%

0.457

0%

2.9%

0.515

Diarrhoea

27.3%

25.7%

0.551

0%

0%

NA

Neutropenia

24.2%

31.4%

0.509

18.2%

31.4%

0.207

Nausea

24.2%

22.9%

0.559

0%

0%

NA

Anorexia

18.2%

20.0%

0.547

0%

0%

NA

Vomiting

12.1%

14.3%

0.539

0%

0%

NA

Fever

12.1%

11.4%

0.611

6.1%

11.4%

0.435

Cough

12.1%

8.6%

0.466

0%

0%

NA

Xerostomia

12.1%

2.9%

0.160

0%

0%

NA

Dizziness

12.1%

0%

0.050

0%

0%

NA

Myalgia

9.1%

22.9%

0.112

0%

0%

NA

Dyspnoea

6.1%

17.1%

0.149

0%

2.9%

0.515

Dyspepsia

6.1%

14.3%

0.239

0%

0%

NA

Mouth ulcers

6.1%

11.4%

0.365

0%

0%

NA

Insomnia

6.1%

8.6%

0.528

0%

0%

NA

Hypersensitivity

6.1%

5.7%

0.670

0%

0%

NA

Herpes Zoster

6.1%

2.9%

0.478

3.0%

0%

0.485

Sore throat

6.1%

2.9%

0.478

0%

0%

NA

Dysgeusia

3.0%

5.7%

0.522

0%

0%

NA

Lower limb oedema

3.0%

5.7%

0.522

0%

2.9%

0.515